Golden
Hyperion Therapeutics

Hyperion Therapeutics

A biopharmaceutical company focused on developing treatments for urea cycle disorders and other rare diseases

All edits

Edits on 26 Mar 2020
Golden AI"Funding autocalculation"
Golden AI edited on 26 Mar 2020 6:59 pm
Edits made to:
Infobox (+1 properties)

Infobox

Total funding amount (USD)
117,471,998
Edits on 25 Jun 2019
Will Suter"Approved suggestion from source: http://www.hyperiontx.com/"
Will Suter approved a suggestion from Golden's AI on 25 Jun 2019 3:32 pm
Edits made to:
Infobox (+1 properties)
Edits on 12 Jun 2019
Golden AI
Golden AI edited on 12 Jun 2019 10:52 pm
Edits made to:
Infobox (+1 properties)
Golden AI
Golden AI edited on 12 Jun 2019 9:33 pm
Edits made to:
Infobox (+1 properties)
Golden AI
Golden AI edited on 12 Jun 2019 9:29 pm
Edits made to:
Infobox (+1 properties)
Edits on 25 Apr 2019
Golden AI
Golden AI edited on 25 Apr 2019 12:52 am
Edits made to:
Infobox (+2 properties)

Infobox

Edits on 31 Mar 2019
Dawson Sewell
Dawson Sewell edited on 31 Mar 2019 12:11 am
Edits made to:
Article (+196/-177 characters)
Related Topics (+1 topics)

Article

On January 5, 2007 Hyperion Therapeutics completed their series A funding round with an undisclosed amount of funding from Sofinnova Ventures, New Enterprise AssociatesNew Enterprise Associates, and Highland Capital PartnersHighland Capital Partners.

...

On September 5, 2007 Hyperion Therapeutics completed their series B funding round with $40 million in funding from Sofinnova Ventures, New Enterprise AssociatesNew Enterprise Associates, Highland Capital PartnersHighland Capital Partners, and Washington Research Foundation.

...

On June 30, 2009 Hyperion Therapeutics completed their series C funding round with $60 million in funding fromBayfrom Bay City Capital (lead investor), Sofinnova Ventures, New Enterprise AssociatesNew Enterprise Associates, Highland Capital PartnersHighland Capital Partners, and Panorama Capital.

...

Acquired by Horizon PharmaPharmaceuticals

On March 30, 2015 Horizon Horizon PharmaPharmaceuticals reached an agreement with Hyperion Therapeutics to purchase the company for $46 per share for approximately $1.1 billion total. The share purchase price of $46 per share was ~35% above Hyperion Therapeutics share price volume weighted average for the previous 60 days.

Related Topics

Dawson Sewell
Dawson Sewell edited on 31 Mar 2019 12:05 am
Edits made to:
Infobox (+6 properties)
Article (+1408 characters)
Further reading (+2 rows) (+8 cells) (+479 characters)
Categories (+1/-2 topics)
Related Topics (+1 topics)

Article

Hyperion Therapeutics is a biopharmaceutical company focused on developing treatments for urea cycle disorders and other rare diseases that is headquartered in South San Francisco, California and was founded in 2006 by Mark Blumling.

Funding

Series A

On January 5, 2007 Hyperion Therapeutics completed their series A funding round with an undisclosed amount of funding from Sofinnova Ventures, New Enterprise Associates, and Highland Capital Partners.

Series B

On September 5, 2007 Hyperion Therapeutics completed their series B funding round with $40 million in funding from Sofinnova Ventures, New Enterprise Associates, Highland Capital Partners, and Washington Research Foundation.

Series C

On June 30, 2009 Hyperion Therapeutics completed their series C funding round with $60 million in funding fromBay City Capital (lead investor), Sofinnova Ventures, New Enterprise Associates, Highland Capital Partners, and Panorama Capital.

Venture

On April 18, 2011 Hyperion Therapeutics completed their venture funding round with $17.5 million in funding from undisclosed investors.

Acquired by Horizon Pharma

On March 30, 2015 Horizon Pharma reached an agreement with Hyperion Therapeutics to purchase the company for $46 per share for approximately $1.1 billion total. The share purchase price of $46 per share was ~35% above Hyperion Therapeutics share price volume weighted average for the previous 60 days.

Further reading

Title
Author
Link
Type

Medicis and Hyperion Therapeutics Announce Strategic Collaboration

Medicis Pharmaceutical Corporation

Web

PRESS RELEASE: Hyperion Therapeutics Announces Senior Management Team and $15M Financing Event

FierceBiotech

Web

Infobox

Categories

Related Topics

Edits on 21 Jan 2019
Golden AI"Changed markets to industries"
Golden AI edited on 21 Jan 2019 10:07 pm
Edits made to:
Infobox (+2/-2 properties)
Edits on 10 Jan 2019
Golden AI
Golden AI edited on 10 Jan 2019 10:21 am
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 12 Dec 2018
Golden AI"Import data"
Golden AI edited on 12 Dec 2018 1:14 am
Edits made to:
Infobox (+3 properties)
People (+5 rows) (+10 cells) (+101 characters)
Categories (+1 topics)

People

Name
Role
Related Golden topics

Bijan Salehizadeh

Investor

Dylan Bird

Investor

Jessica Lemus

Employee

Kevin Weber

Employee

Yen Nguyen

Employee

Infobox

Categories

Edits on 19 Jul 2018
Golden AI"Update locations in infobox"
Golden AI edited on 19 Jul 2018 8:53 pm
Edits on 16 Jul 2018
Golden AI"Update markets in infobox"
Golden AI edited on 16 Jul 2018 11:38 pm

Infobox

Edits on 29 Jun 2018
Golden AI"Update infobox"
Golden AI edited on 29 Jun 2018 5:51 pm
Edits on 18 Jun 2018
Golden AI"Updating description"
Golden AI edited on 18 Jun 2018 10:52 pm
Edits made to:
Description (+109/-21 characters)
Topic thumbnail

Hyperion Therapeutics

Biotechnology company

A biopharmaceutical company focused on developing treatments for urea cycle disorders and other rare diseases

Edits on 29 May 2018
Golden AI"Initial topic creation"
Golden AI created this topic on 29 May 2018 9:29 pm
Edits made to:
Description (+21 characters)
Categories (+1 topics)
Topic thumbnail

 Hyperion Therapeutics

Biotechnology company

Categories

No more activity to show.